These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 30828023)

  • 1. [Verification of Pharmacokinetic Approaches in Prior Drug Development].
    Iga K
    Yakugaku Zasshi; 2019; 139(3):437-460. PubMed ID: 30828023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery.
    Li C; Liu B; Chang J; Groessl T; Zimmerman M; He YQ; Isbell J; Tuntland T
    Drug Discov Today; 2013 Jan; 18(1-2):71-8. PubMed ID: 22982770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction.
    Iga K; Kiriyama A
    Biol Pharm Bull; 2017 Dec; 40(12):2024-2037. PubMed ID: 28993551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics/pharmacodynamics model-supported early drug development.
    Chen B; Dong JQ; Pan WJ; Ruiz A
    Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Projecting ADME Behavior and Drug-Drug Interactions in Early Discovery and Development: Application of the Extended Clearance Classification System.
    El-Kattan AF; Varma MV; Steyn SJ; Scott DO; Maurer TS; Bergman A
    Pharm Res; 2016 Dec; 33(12):3021-3030. PubMed ID: 27620173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics in Drug Discovery: An Exposure-Centred Approach to Optimising and Predicting Drug Efficacy and Safety.
    Reichel A; Lienau P
    Handb Exp Pharmacol; 2016; 232():235-60. PubMed ID: 26330260
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reaction phenotyping to assess victim drug-drug interaction risks.
    Di L
    Expert Opin Drug Discov; 2017 Nov; 12(11):1105-1115. PubMed ID: 28820269
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the relationship between pharmacokinetics and pharmacodynamics in drug development and therapeutic equivalence: a PEARRL review.
    Loisios-Konstantinidis I; Paraiso RLM; Fotaki N; McAllister M; Cristofoletti R; Dressman J
    J Pharm Pharmacol; 2019 Apr; 71(4):699-723. PubMed ID: 30793317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
    Zhao L; Shang EY; Sahajwalla CG
    J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Probe ADME and test hypotheses: a PATH beyond clearance in vitro-in vivo correlations in early drug discovery.
    Bell LC; Wang J
    Expert Opin Drug Metab Toxicol; 2012 Sep; 8(9):1131-55. PubMed ID: 22681474
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Understanding the transport properties of metabolites: case studies and considerations for drug development.
    Zamek-Gliszczynski MJ; Chu X; Polli JW; Paine MF; Galetin A
    Drug Metab Dispos; 2014 Apr; 42(4):650-64. PubMed ID: 24346835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics and Pharmacodynamics in Breast Cancer Animal Models.
    Wang W; Nag S; Zhang R
    Methods Mol Biol; 2016; 1406():271-87. PubMed ID: 26820963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro and in vivo approaches to characterize transporter-mediated disposition in drug discovery.
    Feng B; Varma MV; Costales C; Zhang H; Tremaine L
    Expert Opin Drug Discov; 2014 Aug; 9(8):873-90. PubMed ID: 24857286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug metabolites as cytochrome p450 inhibitors: a retrospective analysis and proposed algorithm for evaluation of the pharmacokinetic interaction potential of metabolites in drug discovery and development.
    Callegari E; Kalgutkar AS; Leung L; Obach RS; Plowchalk DR; Tse S
    Drug Metab Dispos; 2013 Dec; 41(12):2047-55. PubMed ID: 23792812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biomarkers, validation and pharmacokinetic-pharmacodynamic modelling.
    Colburn WA; Lee JW
    Clin Pharmacokinet; 2003; 42(12):997-1022. PubMed ID: 12959633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Meta-analysis of hepatic cytochrome P450 ontogeny to underwrite the prediction of pediatric pharmacokinetics using physiologically based pharmacokinetic modeling.
    Upreti VV; Wahlstrom JL
    J Clin Pharmacol; 2016 Mar; 56(3):266-83. PubMed ID: 26139104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
    Singh AP; Shin YG; Shah DK
    Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical pharmacokinetic/pharmacodynamic modeling and simulation in the pharmaceutical industry: an IQ consortium survey examining the current landscape.
    Schuck E; Bohnert T; Chakravarty A; Damian-Iordache V; Gibson C; Hsu CP; Heimbach T; Krishnatry AS; Liederer BM; Lin J; Maurer T; Mettetal JT; Mudra DR; Nijsen MJ; Raybon J; Schroeder P; Schuck V; Suryawanshi S; Su Y; Trapa P; Tsai A; Vakilynejad M; Wang S; Wong H
    AAPS J; 2015 Mar; 17(2):462-73. PubMed ID: 25630504
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics.
    Fan J; de Lannoy IA
    Biochem Pharmacol; 2014 Jan; 87(1):93-120. PubMed ID: 24055064
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.